Recent News

• 04.23.2025 - Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 04.16.2025 - Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
• 03.26.2025 - Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
• 03.11.2025 - Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
• 03.04.2025 - Viking Therapeutics to Participate at Upcoming Investor Conferences

Recent Filings

• 04.23.2025 - DEFR14A Revised definitive proxy soliciting materials
• 04.23.2025 - 8-K Current report
• 04.23.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.23.2025 - 8-K Current report
• 04.23.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.23.2025 - EX-99.1 EX-99.1
• 04.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.08.2025 - 4/A Statement of changes in beneficial ownership of securities
• 04.08.2025 - ARS Annual Report to Security Holders